HYDERGINE LC
Clinical safety rating: caution
Comprehensive clinical and safety monograph for HYDERGINE LC (HYDERGINE LC).
Ergoloid mesylates (dihydroergotoxine) act as a partial agonist/antagonist at dopamine (D1, D2), serotonin (5-HT1, 5-HT2), and alpha-adrenergic receptors. They enhance cerebral metabolism and increase blood flow via vasodilation and neuroprotection.
| Metabolism | Extensively metabolized in the liver via cytochrome P450 (CYP3A4) to multiple inactive metabolites. First-pass effect results in low systemic bioavailability. |
| Excretion | Renal (80% as metabolites, <1% unchanged); biliary/fecal (20%). |
| Half-life | Terminal elimination half-life: 12–15 hours. Clinical context: steady-state achieved in 2–3 days; allows once-daily dosing. |
| Protein binding | ~42% bound to plasma proteins (primarily albumin). |
| Volume of Distribution | Vd: ~120 L (1.7 L/kg for 70 kg). Clinical meaning: extensive tissue distribution. |
| Bioavailability | Oral: 5–10% (extensive first-pass metabolism); sublingual: 25–30%. |
| Onset of Action | Oral: 1–2 hours; sublingual: 15–30 minutes. |
| Duration of Action | Duration: 8–12 hours after single dose. Clinical notes: cognitive effects persist for several hours; chronic therapy required for dementia indication. |
Oral, 1 mg three times daily. Titrate up to 2 mg three times daily if needed.
| Dosage form | CAPSULE |
| Renal impairment | No specific guidelines; use with caution in severe renal impairment (CrCl <30 mL/min) due to potential accumulation. |
| Liver impairment | Avoid use in severe hepatic impairment (Child-Pugh class C). In moderate impairment (Child-Pugh class B), reduce dose by 50% and monitor. |
| Pediatric use | Safety and efficacy in pediatric patients have not been established; not recommended for use in children. |
| Geriatric use | Initiate at low end of dosing range (1 mg once or twice daily) due to increased sensitivity and risk of orthostatic hypotension; titrate slowly. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for HYDERGINE LC (HYDERGINE LC).
| Breastfeeding | Contraindicated during breastfeeding. Ergot alkaloids suppress prolactin and may cause ergotism in infants (vomiting, diarrhea, weak pulse). M/P ratio: not established; likely >1 due to lipid solubility. |
| Teratogenic Risk | Category X. Contraindicated in pregnancy due to ergot alkaloid-mediated uterine hypertonicity, placental insufficiency, and potential fetal hypoxia. First trimester: risk of spontaneous abortion. Second/third trimesters: fetal growth restriction, preterm labor, neonatal ergotism (convulsions, respiratory depression). |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to ergoloid mesylates or ergot alkaloids.","Severe hypotension, bradycardia, or recent myocardial infarction.","Concomitant use of potent CYP3A4 inhibitors (e.g., macrolides, azole antifungals, protease inhibitors) due to risk of ergotism (vasospasm, ischemia)."]
| Precautions | ["May cause hypotension, bradycardia, or arrhythmias, especially with parenteral use.","Use with caution in cardiovascular disease, hepatic impairment, or renal insufficiency.","May exacerbate psychosis or confusional states in elderly patients.","Avoid concurrent use with vasoconstrictors (e.g., ergot derivatives, triptans) due to risk of severe hypertension."] |
Loading safety data…
| Fetal Monitoring |
| Monitor uterine activity, fetal heart rate, and maternal blood pressure. Discontinue immediately if signs of uterine hypertonicity or fetal distress. Avoid use in pregnancy; no routine monitoring recommended due to contraindication. |
| Fertility Effects | May impair fertility by inhibiting prolactin secretion, leading to anovulation and luteal phase defects. Reversible upon discontinuation. |